| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 500mg | |||
| 1g | |||
| Other Sizes |
| ln Vitro |
In the cytotoxicity assay against human lung cancer A549 cells and human colon cancer HCT116 cells, isonahydrocairitin (compound 7) did not show obvious anti-proliferative effects within the concentration range and time used (cells treated for 48 hours, tested by MTT assay). Unlike compounds 5, 8-13, 16, 18, 20-21, 23-24, and 26 which showed obvious anti-proliferative effects, isonahydrocairitin was among the compounds with no significant antitumor activity. [1]
|
|---|---|
| Cell Assay |
The cytotoxicity of isonahydrocairitin was evaluated using the MTT assay. Human lung cancer A549 cells and human colon cancer HCT116 cells were treated with a series of concentrations of the compound for 48 hours. The inhibitory rate was detected. No obvious anti-proliferative effect was observed for isonahydrocairitin under the tested conditions. [1]
|
| References | |
| Additional Infomation |
Reports indicate that Sophora flavescens contains isodehydrated icariin, and relevant data is available for reference.
isonahydrocairitin (compound 7) is one of the 27 flavonoids isolated from Sophora flavescens. In the structure-activity relationship discussion, the authors noted that isoflavones and pterocarpines (the class to which this compound may belong, though not explicitly stated) did not have significant cytotoxicity in this experiment, suggesting a possible link to the absence of lavandulyl and isopentenyl substituents. [1] |
| Molecular Formula |
C21H20O6
|
|---|---|
| Exact Mass |
368.125
|
| CAS # |
28610-30-2
|
| PubChem CID |
5322079
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
610.4±55.0 °C at 760 mmHg
|
| Melting Point |
275 ºC
|
| Flash Point |
217.9±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.657
|
| Source |
Originated from plants: Berberidaceae Epimedium brevicornu Maxim.
|
| LogP |
4.65
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
612
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CCC1=C(C=C(C2=C1OC(=C(C2=O)O)C3=CC=C(C=C3)O)O)OC)C
|
| InChi Key |
RJANATGWWPNKAL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H20O6/c1-11(2)4-9-14-16(26-3)10-15(23)17-18(24)19(25)20(27-21(14)17)12-5-7-13(22)8-6-12/h4-8,10,22-23,25H,9H2,1-3H3
|
| Chemical Name |
3,5-dihydroxy-2-(4-hydroxyphenyl)-7-methoxy-8-(3-methylbut-2-enyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL (~135.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
